Literature DB >> 1672668

Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.

E Tagliabue1, F Centis, M Campiglio, A Mastroianni, S Martignone, R Pellegrini, P Casalini, C Lanzi, S Ménard, M I Colnaghi.   

Abstract

In order to obtain further information on the biological role of the HER2/neu oncoprotein monoclonal antibodies (MAbs) were produced against the p185 extracellular domain. To immunize the mice and screen the hybridoma supernatants we selected a lung adenocarcinoma cell line (Calu-3), which demonstrated an over-expression of p185HER2 measured as the reactivity with polyclonal rabbit serum to the 14-amino-acid carboxy-terminal-HER2/neu. Two MAbs, designated MGR2 (IgG1) and MGR3 (IgG2), selected for reactivity on Calu-3 and negativity on A43I live cells, the reference target cell for EGF receptor expression, were found to immunoprecipitate a 185-kDa molecule. Immunodepletion experiments with the polyclonal antiserum and cross-competition experiments indicated that the 2 reagents recognized 2 different epitopes located on the p185HER2 molecule. One of the 2 MAbs, MGR3, was found to internalize, induce p185HER2 phosphorylation and inhibit tumor cell growth in vitro. These results indicate that MGR3 is directed against a determinant located in the p185HER2 ligand binding site and may compete with the p185HER2 ligand, but is incapable of inducing a complete mitotic signal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672668     DOI: 10.1002/ijc.2910470625

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

2.  Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.

Authors:  U Srinivas; E Tagliabue; M Campiglio; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

3.  Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.

Authors:  D B Ring; S T Hsieh-Ma; T Shi; J Reeder
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.

Authors:  Gennaro Riccio; Chiara D'Avino; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2012-12-11       Impact factor: 1.650

Review 5.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 6.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

7.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

Authors:  Chiara D'Avino; Rolando Paciello; Gennaro Riccio; Carmela Coppola; Melina Coppola; Paolo Laccetti; Nicola Maurea; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2014-01-12       Impact factor: 1.650

9.  Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs.

Authors:  P Perego; A Boiardi; N Carenini; M De Cesare; E Dolfini; I Magnani; S Martignone; A Silvani; C Soranzo
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

Authors:  E Hurwitz; I Stancovski; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.